(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.85%) $83.14
(1.30%) $1.948
(-0.18%) $2 343.00
(0.11%) $27.57
(0.76%) $929.10
(-0.31%) $0.932
(-0.42%) $10.98
(-0.42%) $0.797
(0.25%) $92.11
Live Chart Being Loaded With Signals
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF...
Stats | |
---|---|
Dagens volum | 99 000.00 |
Gjennomsnittsvolum | 488 822 |
Markedsverdi | 17.40B |
EPS | ¥0 ( 2024-02-08 ) |
Neste inntjeningsdato | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥13.00 ( 2021-12-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -4.55 |
ATR14 | ¥0.925 (0.27%) |
Volum Korrelasjon
Taiko Pharmaceutical Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Taiko Pharmaceutical Korrelasjon - Valuta/Råvare
Taiko Pharmaceutical Økonomi
Annual | 2022 |
Omsetning: | ¥5.04B |
Bruttogevinst: | ¥1.08B (21.41 %) |
EPS: | ¥-112.24 |
FY | 2022 |
Omsetning: | ¥5.04B |
Bruttogevinst: | ¥1.08B (21.41 %) |
EPS: | ¥-112.24 |
FY | 2021 |
Omsetning: | ¥10.72B |
Bruttogevinst: | ¥2.75B (25.63 %) |
EPS: | ¥-91.46 |
FY | 2020 |
Omsetning: | ¥17.68B |
Bruttogevinst: | ¥12.42B (70.24 %) |
EPS: | ¥89.18 |
Financial Reports:
No articles found.
Taiko Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
First Dividend | ¥0.556 | 2009-03-26 |
Last Dividend | ¥13.00 | 2021-12-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | ¥72.22 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.18 | -- |
Div. Sustainability Score | 0.484 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7956.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
7187.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
6432.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
5411.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4433.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
3612.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
2818.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
1446.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9740.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
8795.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.375 | 1.500 | -7.50 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.144 | 1.200 | -4.80 | -5.76 | [0 - 0.3] |
returnOnEquityTTM | -0.261 | 1.500 | -4.01 | -6.02 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.19 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.54 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.719 | 1.500 | 1.560 | 2.34 | [0.2 - 2] |
debtRatioTTM | 0.188 | -1.500 | 6.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -85.89 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
freeCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 20] |
debtEquityRatioTTM | 0.305 | -1.500 | 8.78 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.394 | 1.000 | 6.76 | 6.76 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.127 | 1.000 | -4.55 | -4.55 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.384 | 0.800 | -0.775 | -0.620 | [0.5 - 2] |
Total Score | 0.484 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -6.82 | 1.000 | -0.790 | 0 | [1 - 100] |
returnOnEquityTTM | -0.261 | 2.50 | -2.58 | -6.02 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.124 | 1.500 | -4.16 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.598 |
Taiko Pharmaceutical
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.